SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
The Value of Improving the Productivity of the Drug Development Process
5 references·7 citing·38 second hop
The Value of Improving the Productivity of the Drug Development Process (2002)The Value of Improving the Productivity o…The price of innovation: new estimates of drug development costs (2003)The price of innovation: new …Returns on Research and Development for 1990s New Drug Introductions (2002)Returns on Research and Devel…Risks in new drug development: Approval success rates for investigational drugs (2001)Risks in new drug development…New drug development in the United States from 1963 to 1999 (2001)New drug development in the U…Cost of innovation in the pharmaceutical industry (1991)Cost of innovation in the pha…How do patent-based measures inform product commercialization? —The case of the United States pharmaceutical industry (2018)How do patent-based measures …Planning operations before market launch for balancing time-to-market and risks in pharmaceutical supply chains (2014)Planning operations before ma…Letting Rivals Come Close or Warding Them Off? The Effects of Substitution Threat on Imitation Deterrence (2011)Letting Rivals Come Close or …Contribution of economic evaluation to decision making in early phases of product development: A methodological and empirical review (2008)Contribution of economic eval…Shareholder returns and the exploration–exploitation dilemma: R&D announcements by biotechnology firms (2007)Shareholder returns and the e…R&D Costs and Returns by Therapeutic Category (2004)R&D Costs and Returns by Ther…Antibacterial research and development in the 21st Century – an industry perspective of the challenges (2004)Antibacterial research and de…Why is big Pharma getting out of antibacterial drug discovery? (2003)Is Technological Change In Medicine Worth It? (2001)Firm growth and R&D expenditure (2009)US Biopharmaceutical Finance and the Sustainability of the Biotech Business Model (2011)US biopharmaceutical finance and the sustainability of the biotech business model (2011)Theory of the firm: Managerial behavior, agency costs and ownership structure (1976)Exploration and Exploitation in Organizational Learning (1991)The Cross-Section of Expected Stock Returns (1992)The Alignment of Contract Terms for Knowledge-Creating and Knowledge-Appropriating Relationship Portfolios (2011)Alliance Experience and Governance Flexibility (2015)Technological Innovation, Firm Performance, and Institutional Context: A Meta-Analysis (2020)Conditional logit analysis of qualitative choice behavior (1972)Qualitative Response Models: A Survey (1994)Sources and Financial Consequences of Radical Innovation: Insights from Pharmaceuticals (2003)The cost of biopharmaceutical R&D: is biotech different? (2007)Essential medicines for universal health coverage (2016)Firm Resources and Sustained Competitive Advantage (1991)Dynamic capabilities and strategic management (1997)Firm resources and sustained competitive advantage (2004)Competition–cooperation interplay during multifirm technology coordination: The effect of firm heterogeneity on conflict and consensus in a technology standards organization (2018)Worlds Apart? Connecting Competitive Dynamics and the Resource-Based View of the Firm (2021)Reconceptualizing Imitation: Implications for Dynamic Capabilities, Innovation, and Competitive Advantage (2022)Guidelines for authors and peer reviewers of economic submissions to the BMJ (1996)Decision Modelling For Health Economic Evaluation (2006)MEDICAL DEVICES EARLY ASSESSMENT METHODS: SYSTEMATIC LITERATURE REVIEW (2014)Innovation at the Intersection of Clinical Trials and Real‐World Data Science to Advance Patient Care (2018)Productivity in pharmaceutical–biotechnology R&D: the role of experience and alliances (2005)Economics of New Oncology Drug Development (2007)Deconstructing the Drug Development Process: The New Face of Innovation (2010)The Economics of Follow-on Drug Research and Development (2004)The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry (2011)Market size and innovation: Effects of Medicare Part D on pharmaceutical research and development (2012)Can the pharmaceutical industry reduce attrition rates? (2004)Clinical development success rates for investigational drugs (2014)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)The Quantity And Quality Of Worldwide New Drug Introductions, 1982–2003 (2006)Investments in Pharmaceuticals Before and After TRIPS (2009)Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation (2017)
this work references cited by second hop

References

  • 2003The price of innovation: new estimates of drug development costs4,264 cited
  • 1991Cost of innovation in the pharmaceutical industry763 cited
  • 2001Risks in new drug development: Approval success rates for investigational drugs450 cited
  • 2002Returns on Research and Development for 1990s New Drug Introductions311 cited
  • 2001New drug development in the United States from 1963 to 1999251 cited

Cited by

  • 2011Letting Rivals Come Close or Warding Them Off? The Effects of Substitution Threat on Imitation Deterrence147 cited
  • 2004R&D Costs and Returns by Therapeutic Category119 cited
  • 2008Contribution of economic evaluation to decision making in early phases of product development: A methodological and empirical review92 cited
  • 2007Shareholder returns and the exploration–exploitation dilemma: R&D announcements by biotechnology firms91 cited
  • 2004Antibacterial research and development in the 21st Century – an industry perspective of the challenges84 cited
  • 2014Planning operations before market launch for balancing time-to-market and risks in pharmaceutical supply chains68 cited
  • 2018How do patent-based measures inform product commercialization? —The case of the United States pharmaceutical industry29 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work